Harald Schmidt

Maastricht Universiteit · Pharmacology

Pharmacology, Medicinal Chemistry, Chemical Biology, Biochemistry, Biology, Medicine, Chemistry

  • 375Impact points

  • 81Publications

  • 215Followers

Research Experience

Jan, 2011
NADPH oxidase in ischemia/reperfusion injury
Maastricht University, Pharmacology
VDDG
Maastricht, Netherlands

Education

Oct, 1983 - Oct, 1987
FU Berlin
Medicine
State Exam
Berlin, Germany
Oct, 1977 - Oct, 1983
University Munich
Pharmacy
State Exam
Munich, Germany
Languages:
German, English, French (some)

Contact Details

Business:
6200 MD Maastricht, Netherlands, Limburg
Institution:
Maastricht Universiteit, Pharmacology

Other

About me:
Harald Schmidt, born 1959, is Head of Pharmacology and the Personalised Medicine Platform at Maastricht University, Maastricht Netherlands. He graduated in both Pharmacy and Medicine before specialising in Clinical and Experimental Pharmacology. In his first postdoc, he discovered the precursor role of L-arginine for endogenous NO. In the early 90’s he continued this work in Chicago with the 1998 Nobel laureate, Ferid Murad. Back in Germany, he joined a Clinical Centre for Research Excellence at the University of Würzburg. Based on his IP, he founded and led as CEO the spin-off, vasopharm, who’s NOS inhibitors now enter the clinic. Since 2000, as head of Pharmacology in Gießen and co-chair of a collaborative research centre, he focuses on novel cardiovascular disease mechanisms including oxidative stress, and since 2005, at Monash, also on proteome-based diagnostics, molecular imaging and mechanisms-based drugs. He organises several international conferences and edits a major German textbook in Pharmacology and has published in the highest impact scientific journals such as nature (2), science, PNAS (numerous), Cell and EMBO J.
Leisure activities:
Golf, pool billiard, tennis, soccer, music, movies, art
Favorite Journals:
PLoS
Journal of Molecular Medicine
Cardiovascular research
Circulation Research
Free Radical Biology Medicine
Favorite Publications:
Schmidt, H.H.H.W., Pollock, J. S., Nakane, M., Gorsky, L. D., Förstermann, U. and Murad, F.: Purification of a soluble isoform of guanylyl cyclase-activating-factor synthase. Proc. Natl. Acad. Sci. U.S.A. 88: 365-369, 1991.

Wilcox, C. S., Welch, W. J., Murad, F., Gross, S. S., Taylor, G., Levi, R. and Schmidt, H.H.H.W.: Nitric oxide synthase in macula densa regulates glomerular capillary pressure. Proc. Natl. Acad. Sci. U.S.A. 89: 11993-11997, 1992.
Schmidt H.H.H.W., Hofmann H., Schindler U., Shutenko Z., Cunningham, D., Feelisch M. No NO from NO synthase. Proc. Natl. Acad. Sci. U.S.A. 93, 13712-13717, 1996

Zabel U, Kleinschnitz C, Oh P, Smolenski A, Nedvetsky P, Kugler P, Walter U, Schnitzer JE, Schmidt HHHW (2002) Calcium-dependent membrane association sensitises soluble guanylyl cyclase to NO. Nature Cell Biol 4, 307-311

Melichar, V.O., Behr-Roussel, D., Zabel, U., Uttenthal, L.O., Rodrigo, J., Rupin, A., Verbeuren, T.J., Kumar, A., Schmidt, H.H.H.W. (2004). Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis. Proc. Natl. Acad. Sci. USA, 101:16671-16676

Schmidt, H.H.H.W. and Walter, U.: NO at work. Cell: 78: 919-925, 1994

Stasch JP, Nedvetsky PI, Schmidt PM, Kumar AHS, Nedvetskaya TY, Meurer S, Deile M, Taye A, Knorr A, Lapp H, Müller H, Turgay Y, Rothkegel C, Kemp-Harper B, Müller-Esterl W, Schmidt HHHW (2006) Targeting the heme-oxidized nitric oxide receptor for selective vasodilation of diseased blood vessels J Clin Invest 116:2552-2561

Evgenov OV, Pacher P, Schmidt PM, Haskó G, Schmidt HHHW, Stasch JP (2006). Nitric oxide-independent stimulators and activators of soluble guanylyl cyclase. Nature Reviews Drug Discovery 5:755-768

Kleinschnitz C, Grund H, Wingler K, Armitage ME, Jones E, Mittal M, Barit D, Schwarz T, Geis C, Kraft P, Barthel K, Schuhmann MK, Herrmann AM, Meuth SG, Stoll G, Meurer S, Schrewe A, Becker L, Gailus-Durner V, Fuchs H, Klopstock T, de Angelis MH, Jandeleit-Dahm K, Shah AM, Weissmann N, Schmidt HH. Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol. 2010 Sep 21;8(9). pii: e1000479. PubMed PMID: 20877715; PubMed Central PMCID: PMC2943442.
Favorite Books:
Getting Things Done (David Allen),
7 Habits (Stephen R. Covey),
Faust I (Goethe),
Pharmakologie & Toxikologie (Schmidt & Estler) ;-)
Teaching activities:
Pharmacology and Drug Therapy
Society memberships:
ESC, ASPET, DGPT, ISH, Deutsche Hochdruckliga, EVBO
Board memberships:
JMM, PLoS One, VHRM
Journal referee:
PNAS, Cell, PLOS One, Circulation, BJP, Circulation Research

Publications

12Next »
Follow

Following

Topics

Browse more researchers

Ch
Bi
Me
Academic Degrees

MD PhD RPharm

Research Keywords

Biomarkers, Diagnostics, Cyclic GMP, Hypertension, Nitric Oxide, Reactive Oxygen Species, Oxidative Stress, Nitric Oxide Synthase, NADPH Oxidase, Stroke, Drug Discovery, soluble guanylate cyclase, anti-pterins

Past Advisors

Eycke Boehme, Günter Schultz, Ferid Murad, Ulrich Walter

Current Location

Maastricht, Netherlands